Associated Papers
Binimetinib, a novel MEK1/2 inhibitor, exerts anti-leukemic effects under inactive status of PI3Kinase/Akt pathway.
Sakakibara K et al.
International Journal of Hematology, 2019
Comprehensive genomic analysis reveals clinically relevant molecular distinctions between thymic carcinomas and thymomas.
Girard N et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2009
Select a paper to view details